Company profile
Sano Genetics Ltd is a UK company with status active founded in 2017 based in London.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
MA | Transaction MzUxMTU0OTI1OWFkaXF6a2N4 | Paper/PDF filed
Published 28 Mar 2026 23:42
RESOLUTIONS | Transaction WUVZN0RDTVBhZGlxemtjeA | Paper/PDF filed
Published 28 Mar 2026 07:46
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NDc3NDE5M2FkaXF6a2N4
Published 25 Nov 2024 01:18
SH01 | Transaction MzQ0NDc3MzM2MWFkaXF6a2N4
Published 25 Nov 2024 01:11
AA | Transaction MzQzNzc5OTQwMmFkaXF6a2N4
Published 30 Sep 2024 05:31
Company registered at Companies House
1 Sep 2023 to 31 Aug 2025
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are becoming increasingly prevalent in the UK, with an estimated 20% of the adult population affected. These conditions are associated with obesity and type 2 diabetes, and can lead to serious liver damage, including cirrhosis and liver cancer. The cost of treating liver di...
1 Oct 2022 to 31 Mar 2024
The clinical trial setup has not changed since the 1980s, since the era of the "blockbuster drug" where patients were recruited with brute force to get statistical significance for market approval. This market was dominated by Big Pharma, which had the funds to bankroll this approach and outsourced the entire process to Contract research organisations ("C...
1 Jul 2022 to 31 Dec 2023
**Speeding genetic neurodegenerative disease research through genetic sequencing standardisation, cross-border patient recruitment and development of ethnically and geographically diverse disease datasets.** Genetic neurodegenerative diseases (GND) such as Motor Neurone Disease(MND), Frontotemporal dementia(FTD), Lewy Body dementia, Alzheimer's disease af...
1 Feb 2021 to 31 Jan 2023
'How severely will my disease develop?' 'How long will I have my sight for?' 'My brother and father lost their sight at 20, will I as well?' Genetic testing has revolutionised the way that individuals with rare and inherited diseases can be diagnosed and managed, but these important questions are frequently asked by patients in eye genetic clinics across ...
1 Jan 2021 to 31 Dec 2021
Public description The COVID-19 crisis has thrown into sharp focus the global inability to predict personalised disease progression i.e. why do some people suffer more severely than others or respond differently to treatments. The reason is complex and due to a combination of genetic, demographic, and phenotypic factors. For nearly every common and rare d...
1 Nov 2020 to 31 Jul 2021
Our inability to predict personalised disease progression (i.e. why do some people suffer more severely than others or respond differently to treatments) drastically reduces our ability to treat complex disease. Personalised medicine requires multiple sources of data on an individual level (including genetics, medical history, and other testing) and the a...
1 Jun 2020 to 31 Oct 2020
Our inability to predict personalised disease progression (i.e. why do some people suffer more severely than others or respond differently to treatments) drastically reduces our ability to treat complex disease. Personalised medicine requires multiple sources of data on an individual level (including genetics, medical history, and other testing) and the a...
1 Oct 2019 to 31 Mar 2021
"We are Sano Genetics, a leading developer of innovative digital health platforms, focussed on DNA and genetic sequencing and data. As the market for DNA sequencing - both public and private (£19.2bn by 2025;19% CAGR-[Allied Market Research][0]:2017) - continues to grow, as does the volume of personal health data stored. Whilst this opens up new opportuni...
